Onyx Pharmaceuticals Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate Merger with Amgen, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the merger of Onyx Pharmaceuticals, Inc. (“Onyx”) (NasdaqGS: ONXX) with Amgen, Inc. for shareholders. Under the terms of the proposed merger agreement, valued at approximately $10.4 billion, Onyx shareholders are expected to receive $125 per share of Onyx common stock owned, well below the 52-week high of $136.87.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, [phone], via email at [e-mail] or Zach Groover at Powers Taylor, LLP, toll free [phone] or via e-mail at [e-mail]. There is no cost or fee to you.

The Onyx sale investigation centers on whether shareholders are receiving adequate compensation for their shares in the proposed deal, whether the transaction properly values Onyx stock, and whether Onyx’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal.

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

The Briscoe Law Firm, PLLCWillie Briscoe, [e-mail] Taylor, LLPZach Groover, [e-mail]